Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

Phase 3

Completed

Conditions: Thromboembolism

Interventions: Drug: Warfarin
Drug: Dabigatran etexilate

Registration Number: NCT00680186

Lead Sponsor: Boehringer Ingelheim

Brief Summary: The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin Pro re nata (As needed/PRN) to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute symptomatic VTE.

The primary objective is to investigate the efficacy of dabigatran compared to warfarin during the 6 month treatment period. The investigation of other selected efficacy aspects and safety are regarded as secondary objective of this trial.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 2589

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Warfarin (INR 2.0-3.0)	Warfarin	Patients will receive tablets PRN warfarin/matching placebo to maintain a target INR of 2.0-3.0
Dabigatran etexilate (150mg bid)	Dabigatran etexilate	Patients will receive 1 capsule containing 150 mg dabigatran etexilate/matching placebo twice daily

Primary Outcome Measures

Name	Time	Method
Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE	For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)	All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Recurrent Symptomatic VTE and All Deaths	For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.	VTE or any death which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.
Number of Participants With Recurrent Symptomatic DVT	For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.	Symptomatic DVT which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.
Number of Participants With Recurrent Symptomatic Non-fatal PE	For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.	Symptomatic non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.
Number of Participants Who Died Due to VTE	From randomisation to 6 months (up to day 180) and to end of ptp (planned to be up to day 224)	VTE - related deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. Hazard ratios and 95% CI were not calculated because of insufficient number of events.
Number of Participants Who Died (Any Cause)	For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.	Any deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.
Number of Participants With Recurrent Symptomatic Fatal and Non-fatal PE	For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.	Symptomatic fatal and non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.
Number of Participants With MBE, MBE and/or CRBE, and Any Bleeding Events	From first intake of study drug to last intake of study drug + 6 days washout	Major bleeding events (MBE) are defined as * Fatal bleeding * Symptomatic bleeding in a critical area or organ * Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells Clinically-relevant bleeding events (CRBE) are defined as * spontaneous skin hematoma \>=25 cm² * wound hematoma \>=100 cm² * spontaneous nose bleed \>5 min * macroscopic hematuria spontaneous or \>24 hours if associated with an intervention * spontaneous rectal bleeding * gingival bleeding \>5 min * leading to hospitalisation and / or requiring surgical treatment * leading to a transfusion of \<2 units of whole blood or red cells * any other bleeding event considered clinically relevant by the investigator Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.
Number of Participants With Acute Coronary Syndrome (ACS)	From first intake of study drug to last contact date	Any ACS occurring during the conduct of the study (centrally adjudicated as definite). Patients having a centrally adjudicated definite ACS during intake of study drug and after stopping study drug, according to treatment group. ACS assessments pre-specified in the protocol without adjudication. Prior to database lock, the steering committee asked to have ACS events adjudicated by an independent committee. After database lock, the committee was provided with source documentation that was blinded to the patient's treatment assignment. ACS results presented are based on adjudication findings.
Laboratory Analyses	From first intake of study drug to last intake of study drug + 6 days washout	Frequency of patients with possible clinically significant abnormalities.

Trial Locations

Locations (220): 1160.46.02021 Boehringer Ingelheim Investigational Site
🇨🇦
Victoria, British Columbia, Canada
1160.46.02004 Boehringer Ingelheim Investigational Site
🇨🇦
Saint John, New Brunswick, Canada
1160.46.02019 Boehringer Ingelheim Investigational Site
🇨🇦
Toronto, Ontario, Canada
1160.46.91006 Boehringer Ingelheim Investigational Site
🇮🇳
Bangalore, India
1160.46.91001 Boehringer Ingelheim Investigational Site
🇮🇳
Pune, India
1160.46.63003 Boehringer Ingelheim Investigational Site
🇵🇭
Quezon City, Philippines
1160.46.42107 Boehringer Ingelheim Investigational Site
🇸🇰
Banska Bystrica, Slovakia
1160.46.42002 Boehringer Ingelheim Investigational Site
🇨🇿
Hradec Kralove, Czech Republic
1160.46.42012 Boehringer Ingelheim Investigational Site
🇨🇿
Liberec, Czech Republic
1160.46.42005 Boehringer Ingelheim Investigational Site
🇨🇿
Ostrava-Vitkovice, Czech Republic
1160.46.42016 Boehringer Ingelheim Investigational Site
🇨🇿
Teplice, Czech Republic
1160.46.91010 Boehringer Ingelheim Investigational Site
🇮🇳
Bangalore, India
1160.46.91012 Boehringer Ingelheim Investigational Site
🇮🇳
Kolkata, India
1160.46.91004 Boehringer Ingelheim Investigational Site
🇮🇳
Pune, India
1160.46.91011 Boehringer Ingelheim Investigational Site
🇮🇳
Tamil Nadu, India
1160.46.65003 Boehringer Ingelheim Investigational Site
🇸🇬
Singapore, Singapore
1160.46.42103 Boehringer Ingelheim Investigational Site
🇸🇰
Nove Zamky, Slovakia
1160.46.66008 Boehringer Ingelheim Investigational Site
🇹🇭
Phayathai, Thailand
1160.46.42018 Boehringer Ingelheim Investigational Site
🇨🇿
Litomerice, Czech Republic
1160.46.42015 Boehringer Ingelheim Investigational Site
🇨🇿
Novy Jicin, Czech Republic
1160.46.42014 Boehringer Ingelheim Investigational Site
🇨🇿
Tabor, Czech Republic
1160.46.42010 Boehringer Ingelheim Investigational Site
🇨🇿
Usti nad Labem, Czech Republic
1160.46.91009 Boehringer Ingelheim Investigational Site
🇮🇳
Ludhiana, India
1160.46.60003 Boehringer Ingelheim Investigational Site
🇲🇾
Melaka, Malaysia
1160.46.66007 Boehringer Ingelheim Investigational Site
🇹🇭
Bangkok, Thailand
1160.46.42001 Boehringer Ingelheim Investigational Site
🇨🇿
Brno, Czech Republic
1160.46.42017 Boehringer Ingelheim Investigational Site
🇨🇿
Prague 4, Czech Republic
1160.46.42007 Boehringer Ingelheim Investigational Site
🇨🇿
Zlin, Czech Republic
1160.46.91007 Boehringer Ingelheim Investigational Site
🇮🇳
Chennai, India
1160.46.91003 Boehringer Ingelheim Investigational Site
🇮🇳
Vadodra, India
1160.46.60001 Boehringer Ingelheim Investigational Site
🇲🇾
Kelantan Kota Bahru, Malaysia
1160.46.91002 Boehringer Ingelheim Investigational Site
🇮🇳
Chennai, India
1160.46.91014 Boehringer Ingelheim Investigational Site
🇮🇳
New Delhi, India
1160.46.91013 Boehringer Ingelheim Investigational Site
🇮🇳
Vadodara, India
1160.46.60004 Boehringer Ingelheim Investigational Site
🇲🇾
Pahang, Malaysia
1160.46.60002 Boehringer Ingelheim Investigational Site
🇲🇾
Selangor, Malaysia
1160.46.47001 Boehringer Ingelheim Investigational Site
🇳🇴
Oslo, Norway
1160.46.66005 Boehringer Ingelheim Investigational Site
🇹🇭
Nakhonratchasima, Thailand
1160.46.86015 Boehringer Ingelheim Investigational Site
🇨🇳
Guangzhou, China
1160.46.86006 Boehringer Ingelheim Investigational Site
🇨🇳
Tianjin, China
1160.46.86017 Boehringer Ingelheim Investigational Site
🇨🇳
Shijiazhuang, China
1160.46.86018 Boehringer Ingelheim Investigational Site
🇨🇳
Shijiazhuang, China
1160.46.02020 Boehringer Ingelheim Investigational Site
🇨🇦
Quebec, Canada
1160.46.82009 Boehringer Ingelheim Investigational Site
🇰🇷
Seoul, Korea, Republic of
1160.46.01044 Boehringer Ingelheim Investigational Site
🇺🇸
Clearwater, Florida, United States
1160.46.01068 Boehringer Ingelheim Investigational Site
🇺🇸
Normal, Illinois, United States
1160.46.01073 Boehringer Ingelheim Investigational Site
🇺🇸
Little Rock, Arkansas, United States
1160.46.01061 Boehringer Ingelheim Investigational Site
🇺🇸
Columbus, Ohio, United States
1160.46.61003 Boehringer Ingelheim Investigational Site
🇦🇺
Box Hill, Victoria, Australia
1160.46.86003 Boehringer Ingelheim Investigational Site
🇨🇳
Shanghai, China
1160.46.55016 Boehringer Ingelheim Investigational Site
🇧🇷
Rio de Janeiro - RJ, Brazil
1160.46.35903 Boehringer Ingelheim Investigational Site
🇧🇬
Sofia, Bulgaria
1160.46.55020 Boehringer Ingelheim Investigational Site
🇧🇷
São Paulo, Brazil
1160.46.35901 Boehringer Ingelheim Investigational Site
🇧🇬
Sofia, Bulgaria
1160.46.97212 Boehringer Ingelheim Investigational Site
🇮🇱
DN Lower Galillee, Israel
1160.46.55018 Boehringer Ingelheim Investigational Site
🇧🇷
São Bernardo do Campo, Brazil
1160.46.02006 Boehringer Ingelheim Investigational Site
🇨🇦
Edmonton, Alberta, Canada
1160.46.86001 Boehringer Ingelheim Investigational Site
🇨🇳
Beijing, China
1160.46.86016 Boehringer Ingelheim Investigational Site
🇨🇳
Hangzhou, China
1160.46.86005 Boehringer Ingelheim Investigational Site
🇨🇳
Shanghai, China
1160.46.86004 Boehringer Ingelheim Investigational Site
🇨🇳
Shanghai, China
1160.46.86019 Boehringer Ingelheim Investigational Site
🇨🇳
Beijing, China
1160.46.86011 Boehringer Ingelheim Investigational Site
🇨🇳
Shanghai, China
1160.46.86007 Boehringer Ingelheim Investigational Site
🇨🇳
Shenyang, China
1160.46.86021 Boehringer Ingelheim Investigational Site
🇨🇳
Taiyuan, China
1160.46.86020 Boehringer Ingelheim Investigational Site
🇨🇳
Yinchuan, China
1160.46.97205 Boehringer Ingelheim Investigational Site
🇮🇱
KfarSaba, Israel
1160.46.97201 Boehringer Ingelheim Investigational Site
🇮🇱
Zerifin, Israel
1160.46.45001 Boehringer Ingelheim Investigational Site
🇩🇰
Aarhus C, Denmark
1160.46.45008 Boehringer Ingelheim Investigational Site
🇩🇰
Esbjerg, Denmark
1160.46.45009 Boehringer Ingelheim Investigational Site
🇩🇰
Holbæk, Denmark
1160.46.3303F Boehringer Ingelheim Investigational Site
🇫🇷
St Etienne Cedex 2, France
1160.46.91005 Boehringer Ingelheim Investigational Site
🇮🇳
New Delhi, India
1160.46.45004 Boehringer Ingelheim Investigational Site
🇩🇰
København NV, Denmark
1160.46.3303B Boehringer Ingelheim Investigational Site
🇫🇷
St Priest En Jarez Cedex, France
1160.46.97202 Boehringer Ingelheim Investigational Site
🇮🇱
Afula, Israel
1160.46.97207 Boehringer Ingelheim Investigational Site
🇮🇱
Ashkelon, Israel
1160.46.36010 Boehringer Ingelheim Investigational Site
🇭🇺
Szekesfehervar, Hungary
1160.46.3303C Boehringer Ingelheim Investigational Site
🇫🇷
St Etienne Cedex 2, France
1160.46.3303G Boehringer Ingelheim Investigational Site
🇫🇷
St Etienne Cedex 2, France
1160.46.3303H Boehringer Ingelheim Investigational Site
🇫🇷
St Etienne Cedex 2, France
1160.46.3301A Boehringer Ingelheim Investigational Site
🇫🇷
Brest Cedex, France
1160.46.3303A Boehringer Ingelheim Investigational Site
🇫🇷
St Priest En Jarez Cedex, France
1160.46.36002 Boehringer Ingelheim Investigational Site
🇭🇺
Debrecen, Hungary
1160.46.97211 Boehringer Ingelheim Investigational Site
🇮🇱
Haifa, Israel
1160.46.3315A Boehringer Ingelheim Investigational Site
🇫🇷
La Roche-Sur-Yon cedex 09, France
1160.46.3303D Boehringer Ingelheim Investigational Site
🇫🇷
St Etienne Cedex 2, France
1160.46.3313A Boehringer Ingelheim Investigational Site
🇫🇷
Nantes, France
1160.46.3301B Boehringer Ingelheim Investigational Site
🇫🇷
Brest Cedex, France
1160.46.3316A Boehringer Ingelheim Investigational Site
🇫🇷
Pessac, France
1160.46.39015 Boehringer Ingelheim Investigational Site
🇮🇹
Firenze, Italy
1160.46.82008 Boehringer Ingelheim Investigational Site
🇰🇷
Gyeonggi-do, Korea, Republic of
1160.46.36011 Boehringer Ingelheim Investigational Site
🇭🇺
Szombathely, Hungary
1160.46.97209 Boehringer Ingelheim Investigational Site
🇮🇱
Nazareth, Israel
1160.46.97203 Boehringer Ingelheim Investigational Site
🇮🇱
Holon, Israel
1160.46.39007 Boehringer Ingelheim Investigational Site
🇮🇹
Reggio Emilia, Italy
1160.46.39005 Boehringer Ingelheim Investigational Site
🇮🇹
Vittorio Veneto (TV), Italy
1160.46.82005 Boehringer Ingelheim Investigational Site
🇰🇷
Seoul, Korea, Republic of
1160.46.31013 Boehringer Ingelheim Investigational Site
🇳🇱
Eindhoven, Netherlands
1160.46.31014 Boehringer Ingelheim Investigational Site
🇳🇱
Heerlen, Netherlands
1160.46.39013 Boehringer Ingelheim Investigational Site
🇮🇹
Verona, Italy
1160.46.97206 Boehringer Ingelheim Investigational Site
🇮🇱
Petah Tiqwa, Israel
1160.46.82003 Boehringer Ingelheim Investigational Site
🇰🇷
Goyang-si, Korea, Republic of
1160.46.97210 Boehringer Ingelheim Investigational Site
🇮🇱
Tel Aviv, Israel
1160.46.97204 Boehringer Ingelheim Investigational Site
🇮🇱
Tel Hashomer, Ramat Gan, Israel
1160.46.82007 Boehringer Ingelheim Investigational Site
🇰🇷
Busan, Korea, Republic of
1160.46.39011 Boehringer Ingelheim Investigational Site
🇮🇹
Catania, Italy
1160.46.39012 Boehringer Ingelheim Investigational Site
🇮🇹
Palermo, Italy
1160.46.82006 Boehringer Ingelheim Investigational Site
🇰🇷
Seoul, Korea, Republic of
1160.46.82002 Boehringer Ingelheim Investigational Site
🇰🇷
Kyunggi-do, Korea, Republic of
1160.46.82010 Boehringer Ingelheim Investigational Site
🇰🇷
Gyeonggi-do, Korea, Republic of
1160.46.31010 Boehringer Ingelheim Investigational Site
🇳🇱
Den Bosch, Netherlands
1160.46.31002 Boehringer Ingelheim Investigational Site
🇳🇱
Nieuwegein, Netherlands
1160.46.64004 Boehringer Ingelheim Investigational Site
🇳🇿
Christchurch, New Zealand
1160.46.07007 Boehringer Ingelheim Investigational Site
🇷🇺
Ekaterinburg, Russian Federation
1160.46.07014 Boehringer Ingelheim Investigational Site
🇷🇺
Ufa, Russian Federation
1160.46.27014 Boehringer Ingelheim Investigational Site
🇿🇦
Kempton Park, South Africa
1160.46.27006 Boehringer Ingelheim Investigational Site
🇿🇦
Sunninghill, South Africa
1160.46.66001 Boehringer Ingelheim Investigational Site
🇹🇭
Khon Kaen, Thailand
1160.46.61001 Boehringer Ingelheim Investigational Site
🇦🇺
Clayton, Victoria, Australia
1160.46.61007 Boehringer Ingelheim Investigational Site
🇦🇺
Concord, New South Wales, Australia
1160.46.3303E Boehringer Ingelheim Investigational Site
🇫🇷
St Etienne Cedex 2, France
1160.46.61006 Boehringer Ingelheim Investigational Site
🇦🇺
Windsor, Victoria, Australia
1160.46.01055 Boehringer Ingelheim Investigational Site
🇺🇸
Summerville, South Carolina, United States
1160.46.02002 Boehringer Ingelheim Investigational Site
🇨🇦
Hamilton, Ontario, Canada
1160.46.02010 Boehringer Ingelheim Investigational Site
🇨🇦
Hamilton, Ontario, Canada
1160.46.35906 Boehringer Ingelheim Investigational Site
🇧🇬
Sofia, Bulgaria
1160.46.02005 Boehringer Ingelheim Investigational Site
🇨🇦
Hamilton, Ontario, Canada
1160.46.3316B Boehringer Ingelheim Investigational Site
🇫🇷
Pessac, France
1160.46.07005 Boehringer Ingelheim Investigational Site
🇷🇺
Yaroslavl, Russian Federation
1160.46.27015 Boehringer Ingelheim Investigational Site
🇿🇦
Krugersdorp, South Africa
1160.46.34011 Boehringer Ingelheim Investigational Site
🇪🇸
Valencia, Spain
1160.46.34009 Boehringer Ingelheim Investigational Site
🇪🇸
Madrid, Spain
1160.46.01063 Boehringer Ingelheim Investigational Site
🇺🇸
Corvallis, Oregon, United States
1160.46.01059 Boehringer Ingelheim Investigational Site
🇺🇸
Bend, Oregon, United States
1160.46.01060 Boehringer Ingelheim Investigational Site
🇺🇸
Stony Brook, New York, United States
1160.46.01071 Boehringer Ingelheim Investigational Site
🇺🇸
Shreveport, Louisiana, United States
1160.46.01062 Boehringer Ingelheim Investigational Site
🇺🇸
Bellevue, Washington, United States
1160.46.55010 Boehringer Ingelheim Investigational Site
🇧🇷
Brasília, Brazil
1160.46.61005 Boehringer Ingelheim Investigational Site
🇦🇺
Perth, Western Australia, Australia
1160.46.55007 Boehringer Ingelheim Investigational Site
🇧🇷
Campinas, Brazil
1160.46.55019 Boehringer Ingelheim Investigational Site
🇧🇷
Porto Alegre, Brazil
1160.46.55014 Boehringer Ingelheim Investigational Site
🇧🇷
Curitiba, Brazil
1160.46.55017 Boehringer Ingelheim Investigational Site
🇧🇷
Curitiba, Brazil
1160.46.55021 Boehringer Ingelheim Investigational Site
🇧🇷
Recife, Brazil
1160.46.35905 Boehringer Ingelheim Investigational Site
🇧🇬
Varna, Bulgaria
1160.46.02013 Boehringer Ingelheim Investigational Site
🇨🇦
Edmonton, Alberta, Canada
1160.46.02008 Boehringer Ingelheim Investigational Site
🇨🇦
Montreal, Quebec, Canada
1160.46.02009 Boehringer Ingelheim Investigational Site
🇨🇦
Montreal, Quebec, Canada
1160.46.02015 Boehringer Ingelheim Investigational Site
🇨🇦
Ottawa, Ontario, Canada
1160.46.02014 Boehringer Ingelheim Investigational Site
🇨🇦
Montreal, Quebec, Canada
1160.46.02017 Boehringer Ingelheim Investigational Site
🇨🇦
Montreal, Quebec, Canada
1160.46.86002 Boehringer Ingelheim Investigational Site
🇨🇳
Beijing, China
1160.46.86014 Boehringer Ingelheim Investigational Site
🇨🇳
Guangzhou, China
1160.46.3315B Boehringer Ingelheim Investigational Site
🇫🇷
La Roche-Sur-Yon cedex 09, France
1160.46.91008 Boehringer Ingelheim Investigational Site
🇮🇳
Nagpur, India
1160.46.82004 Boehringer Ingelheim Investigational Site
🇰🇷
Seoul, Korea, Republic of
1160.46.31017 Boehringer Ingelheim Investigational Site
🇳🇱
Alkmaar, Netherlands
1160.46.31001 Boehringer Ingelheim Investigational Site
🇳🇱
Amersfoort, Netherlands
1160.46.64001 Boehringer Ingelheim Investigational Site
🇳🇿
Takapuna Auckland, New Zealand
1160.46.31015 Boehringer Ingelheim Investigational Site
🇳🇱
Zwolle, Netherlands
1160.46.31004 Boehringer Ingelheim Investigational Site
🇳🇱
Rotterdam, Netherlands
1160.46.64003 Boehringer Ingelheim Investigational Site
🇳🇿
Grafton Auckland, New Zealand
1160.46.64002 Boehringer Ingelheim Investigational Site
🇳🇿
Otahuhu Auckland, New Zealand
1160.46.47005 Boehringer Ingelheim Investigational Site
🇳🇴
Trondheim, Norway
1160.46.63001 Boehringer Ingelheim Investigational Site
🇵🇭
Manila, Philippines
1160.46.63005 Boehringer Ingelheim Investigational Site
🇵🇭
Muntinlupa, Philippines
1160.46.63004 Boehringer Ingelheim Investigational Site
🇵🇭
Quezon City, Philippines
1160.46.48005 Boehringer Ingelheim Investigational Site
🇵🇱
Krakow, Poland
1160.46.48004 Boehringer Ingelheim Investigational Site
🇵🇱
Kielce, Poland
1160.46.48003 Boehringer Ingelheim Investigational Site
🇵🇱
Poznan, Poland
1160.46.48006 Boehringer Ingelheim Investigational Site
🇵🇱
Warsaw, Poland
1160.46.07021 Boehringer Ingelheim Investigational Site
🇷🇺
Chelyabinsk, Russian Federation
1160.46.07004 Boehringer Ingelheim Investigational Site
🇷🇺
Kursk, Russian Federation
1160.46.07016 Boehringer Ingelheim Investigational Site
🇷🇺
Krasnodar, Russian Federation
1160.46.07009 Boehringer Ingelheim Investigational Site
🇷🇺
Rostov-na-Donu, Russian Federation
1160.46.07024 Boehringer Ingelheim Investigational Site
🇷🇺
Rostov-na-Donu, Russian Federation
1160.46.07006 Boehringer Ingelheim Investigational Site
🇷🇺
Yaroslavl, Russian Federation
1160.46.65001 Boehringer Ingelheim Investigational Site
🇸🇬
Singapore, Singapore
1160.46.65002 Boehringer Ingelheim Investigational Site
🇸🇬
Singapore, Singapore
1160.46.42106 Boehringer Ingelheim Investigational Site
🇸🇰
Lucenec, Slovakia
1160.46.42102 Boehringer Ingelheim Investigational Site
🇸🇰
Nitra, Slovakia
1160.46.27001 Boehringer Ingelheim Investigational Site
🇿🇦
Bryanston, South Africa
1160.46.27013 Boehringer Ingelheim Investigational Site
🇿🇦
Cape Town, South Africa
1160.46.27007 Boehringer Ingelheim Investigational Site
🇿🇦
Centurion, South Africa
1160.46.27002 Boehringer Ingelheim Investigational Site
🇿🇦
Morningside, South Africa
1160.46.27012 Boehringer Ingelheim Investigational Site
🇿🇦
Plumstead, South Africa
1160.46.34002 Boehringer Ingelheim Investigational Site
🇪🇸
Barcelona, Spain
1160.46.34007 Boehringer Ingelheim Investigational Site
🇪🇸
Cartagena. Murcia, Spain
1160.46.34015 Boehringer Ingelheim Investigational Site
🇪🇸
Palma de Mallorca, Spain
1160.46.46001 Boehringer Ingelheim Investigational Site
🇸🇪
Stockholm, Sweden
1160.46.34014 Boehringer Ingelheim Investigational Site
🇪🇸
Sabadell - barcelona, Spain
1160.46.46002 Boehringer Ingelheim Investigational Site
🇸🇪
Göteborg, Sweden
1160.46.46010 Boehringer Ingelheim Investigational Site
🇸🇪
Kristianstad, Sweden
1160.46.88606 Boehringer Ingelheim Investigational Site
🇨🇳
Taipei, Taiwan
1160.46.46003 Boehringer Ingelheim Investigational Site
🇸🇪
Uppsala, Sweden
1160.46.46008 Boehringer Ingelheim Investigational Site
🇸🇪
Stockholm, Sweden
1160.46.88604 Boehringer Ingelheim Investigational Site
🇨🇳
Taipei, Taiwan
1160.46.88607 Boehringer Ingelheim Investigational Site
🇨🇳
ChangHua, Taiwan
1160.46.88609 Boehringer Ingelheim Investigational Site
🇨🇳
Taipei, Taiwan
1160.46.88608 Boehringer Ingelheim Investigational Site
🇨🇳
Taipei, Taiwan
1160.46.66010 Boehringer Ingelheim Investigational Site
🇹🇭
Bangkok, Thailand
1160.46.66004 Boehringer Ingelheim Investigational Site
🇹🇭
Muang Nakhonratchasima, Thailand
1160.46.66006 Boehringer Ingelheim Investigational Site
🇹🇭
Nokorn Nayok, Thailand
1160.46.90003 Boehringer Ingelheim Investigational Site
🇹🇷
Ankara, Turkey
1160.46.90001 Boehringer Ingelheim Investigational Site
🇹🇷
Istanbul, Turkey
1160.46.90002 Boehringer Ingelheim Investigational Site
🇹🇷
Istanbul, Turkey
1160.46.90008 Boehringer Ingelheim Investigational Site
🇹🇷
Istanbul, Turkey
1160.46.90007 Boehringer Ingelheim Investigational Site
🇹🇷
Istanbul, Turkey
1160.46.90009 Boehringer Ingelheim Investigational Site
🇹🇷
Istanbul, Turkey
1160.46.90004 Boehringer Ingelheim Investigational Site
🇹🇷
Ankara, Turkey
1160.46.90010 Boehringer Ingelheim Investigational Site
🇹🇷
Istanbul, Turkey
1160.46.38005 Boehringer Ingelheim Investigational Site
🇺🇦
Vinnitsa, Ukraine
1160.46.44005 Boehringer Ingelheim Investigational Site
🇬🇧
Headington, Oxford, United Kingdom
1160.46.44006 Boehringer Ingelheim Investigational Site
🇬🇧
Newcastle upon Tyne, United Kingdom
1160.46.44011 Boehringer Ingelheim Investigational Site
🇬🇧
London, United Kingdom
1160.46.44012 Boehringer Ingelheim Investigational Site
🇬🇧
Sheffield, United Kingdom
1160.46.44013 Boehringer Ingelheim Investigational Site
🇬🇧
Plymouth, United Kingdom
1160.46.02001 Boehringer Ingelheim Investigational Site
🇨🇦
Halifax, Nova Scotia, Canada
1160.46.48001 Boehringer Ingelheim Investigational Site
🇵🇱
Krakow, Poland